ClinicalTrials.gg
CompletedNCT00116688Updated Dec 18, 2013Results posted

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

A Phase 3 interventional study of Romiplostim in Thrombocytopenia and Idiopathic Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2013-12-18.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: ThrombocytopeniaReclassifiedWhy we changed it
Registry
Thrombocytopenia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's listed conditions name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Thrombocytopenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
3rd of 29
313 · median 62
Started
2004
the only one that year
Phase 3
13 of 29
1 open now
Registered
4th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 13 in phase 3, and was the 4th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. Participants must have previously completed a romiplostim ITP study.

03

Conditions studied

  • Thrombocytopenia
  • Idiopathic Thrombocytopenic Purpura

Browse trials for

Keywords

  • Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytopenic
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 313 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thrombocytopenia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have previously completed a romiplostim ITP study
  • count ≤ 50 x 10 \^9/L
  • Written

Exclusion criteria

Exclusion Criteria:

  • Bone marrow stem cell disorder or new active diagnosed since enrollment in the previous romiplostim ITP study
  • Received any alkylating agents within 4 weeks before screening visit or anticipated use during the time of the proposed study
  • Currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous romiplostim ITP study), or subject is receiving other agent(s) other than romiplostim
  • Not using adequate precautions
  • Not available for follow-up assessments
  • Has any kind of disorder that compromises the ability of the participant to give and does not have a legally-acceptable representative and/or is unable to comply with study procedures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.

    Biological: Romiplostim

Interventions

  • BiologicalRomiplostim

    Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

    Also known as: AMG 531, Nplate

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Participants with one or more occurrences of one or more adverse events up to 8 weeks after the end of treatment. Participants with more than one event were only counted once.

    Time frame: Duration of treatment plus 8 weeks (up to 285 weeks)

Secondary outcomes

  1. Number of Participants With a Platelet Response

    Platelet response was defined as having a platelet count of ≥ 50 x 10\^9/L at any time on study, excluding platelet counts within 8 weeks after receiving any rescue medications.

    Time frame: Duration of treatment (up to 277 weeks)

  2. Number of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies

    The number of participants with a reduction or discontinuation of concurrent immune (idiopathic) thrombocytopenic purpura (ITP) therapies (corticosteroids, danazol, azathioprine) during the study.

    Time frame: Duration of treatment (up to 277 weeks)

  3. Change From Baseline in ITP Patient Assessment Questionnaire

    The ITP Patient Assessment Questionnaire (ITP-PAQ) assesses ITP-specific health-related quality of life (HRQOL). This questionnaire assesses ITP specific health-related quality of life (HRQOL). The questionnaire consists of 44 items and has six domains: These domains assess the impact of ITP on Physical Health, Mental Health, Work, Social Activity, Women's Health and Overall QOL. The impact of ITP on Physical Health consists of four sub-scales, which evaluate ITP related Symptoms, Fatigue, Bother and Activity. The impact of ITP on Mental Health consists of two sub-scales, which evaluate Psychological distress and Fear in a population with ITP. Items are scored from 0-100 with higher scores indicating better HRQOL.

    Time frame: Baseline to Week 48

  4. Change From Baseline in Short Form 36 (SF-36)

    The SF-36 is a widely used generic health-related quality of life measure. It has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Items are scored from 0 to 100 with higher scores indicating better health status.

    Time frame: Baseline to Week 48

  5. Change From Baseline in Euroqol-5D (EQ-5D) Index Score

    The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The instrument is applicable to a wide range of health conditions and treatments and results in a single index score and a visual analog scale (VAS) score. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension comprises three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state is defined by combining one level from each of the five dimensions. EQ-5D index values range from -0.59 to 1.00. Higher EQ-5D Index scores represent better health status.

    Time frame: Baseline to Week 48

  6. Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)

    The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The EQ-5D VAS records the respondent's self-rated health status on a vertical graduated (0-100) visual analogue scale. Higher EQ-5D VAS scores represent better health status.

    Time frame: Baseline to Week 48

  7. Patient Global Assessment

    The Patient Global Assessment is two questions which assess the overall health-related quality of life (HRQOL) and symptoms of the patient. Each item is answered on a 15-point Likert scale ranging from 'A very great deal worse' (1) to 'A very great deal better' (15). A higher score indicates that quality of life or symptoms have improved.

    Time frame: Week 1 and Week 48

08

Results

Posted Apr 6, 2011

Participant flow

Participants were enrolled from 2 August 2004 through 15 April 2009

Participant flow — Overall Study
MilestoneRomiplostim in AdultsRomiplostim in Pediatric Population
Started29221
Received study medication29120
Completed20017
Not completed924
Withdrew: Protocol deviation10
Withdrew: Noncompliance31
Withdrew: Adverse event110
Withdrew: Withdrawal by subject262
Withdrew: Requirement for alternative therapy111
Withdrew: Physician decision70
Withdrew: Lost to follow-up30
Withdrew: Death150
Withdrew: Protocol-specified criteria30
Withdrew: Pregnancy10
Withdrew: Other110

Outcome measures

PrimaryNumber of Participants With Adverse Events

Participants with one or more occurrences of one or more adverse events up to 8 weeks after the end of treatment. Participants with more than one event were only counted once.

Time frame:
Duration of treatment plus 8 weeks (up to 285 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsRomiplostim in AdultsRomiplostim in Pediatric Population
Number of Participants With Adverse Events28419
SecondaryNumber of Participants With a Platelet Response

Platelet response was defined as having a platelet count of ≥ 50 x 10\^9/L at any time on study, excluding platelet counts within 8 weeks after receiving any rescue medications.

Time frame:
Duration of treatment (up to 277 weeks)
Reported as:
Number · Participants
Number of Participants With a Platelet Response
ParticipantsRomiplostim in AdultsRomiplostim in Pediatric Population
Number of Participants With a Platelet Response27520
SecondaryNumber of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies

The number of participants with a reduction or discontinuation of concurrent immune (idiopathic) thrombocytopenic purpura (ITP) therapies (corticosteroids, danazol, azathioprine) during the study.

Time frame:
Duration of treatment (up to 277 weeks)
Reported as:
Number · Participants
Number of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies
ParticipantsRomiplostim in AdultsRomiplostim in Pediatric Population
Number of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies301
SecondaryChange From Baseline in ITP Patient Assessment Questionnaire

The ITP Patient Assessment Questionnaire (ITP-PAQ) assesses ITP-specific health-related quality of life (HRQOL). This questionnaire assesses ITP specific health-related quality of life (HRQOL). The questionnaire consists of 44 items and has six domains: These domains assess the impact of ITP on Physical Health, Mental Health, Work, Social Activity, Women's Health and Overall QOL. The impact of ITP on Physical Health consists of four sub-scales, which evaluate ITP related Symptoms, Fatigue, Bother and Activity. The impact of ITP on Mental Health consists of two sub-scales, which evaluate Psychological distress and Fear in a population with ITP. Items are scored from 0-100 with higher scores indicating better HRQOL.

Time frame:
Baseline to Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in ITP Patient Assessment Questionnaire
scores on a scaleRomiplostim in Adults
Physical Health Symptoms (N=209)4.20 ± 13.15
Physical Health Fatigue (N=208)3.99 ± 16.00
Physical Health Bother (N=204)6.43 ± 17.39
Physical Health Activity (N=208)5.23 ± 21.08
Emotional Health Psychological (N=208)4.01 ± 15.81
Emotional Health Fear (N=209)3.48 ± 12.59
Overall Quality of Life (N=210)8.32 ± 19.65
Social Quality of Life (N=209)3.89 ± 13.41
Women's Reproductive Health (N=71)4.51 ± 16.35
Work Quality of Life (N=75)2.78 ± 14.54
SecondaryChange From Baseline in Short Form 36 (SF-36)

The SF-36 is a widely used generic health-related quality of life measure. It has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Items are scored from 0 to 100 with higher scores indicating better health status.

Time frame:
Baseline to Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 (SF-36)
scores on a scaleRomiplostim in Adults
Physical Functioning (N=206)1.38 ± 6.34
Role-Physical (N=208)2.03 ± 8.89
Bodily Pain (N=206)0.94 ± 7.99
General Health Perception (N=208)1.31 ± 7.03
Vitality (N=208)1.68 ± 7.47
Social Functioning (N=208)0.52 ± 8.21
Role-Emotional (N=205)1.75 ± 12.22
Mental Health Index (N=208)0.91 ± 7.45
Physical Component Summary (N=200)1.49 ± 6.51
Mental Component Summary (N=200)1.06 ± 8.80
SecondaryChange From Baseline in Euroqol-5D (EQ-5D) Index Score

The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The instrument is applicable to a wide range of health conditions and treatments and results in a single index score and a visual analog scale (VAS) score. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension comprises three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state is defined by combining one level from each of the five dimensions. EQ-5D index values range from -0.59 to 1.00. Higher EQ-5D Index scores represent better health status.

Time frame:
Baseline to Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Euroqol-5D (EQ-5D) Index Score
scores on a scaleRomiplostim in Adults
Change From Baseline in Euroqol-5D (EQ-5D) Index Score0.03 ± 0.16
SecondaryChange From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)

The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The EQ-5D VAS records the respondent's self-rated health status on a vertical graduated (0-100) visual analogue scale. Higher EQ-5D VAS scores represent better health status.

Time frame:
Baseline to Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)
scores on a scaleRomiplostim in Adults
Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)6.05 ± 14.85
SecondaryPatient Global Assessment

The Patient Global Assessment is two questions which assess the overall health-related quality of life (HRQOL) and symptoms of the patient. Each item is answered on a 15-point Likert scale ranging from 'A very great deal worse' (1) to 'A very great deal better' (15). A higher score indicates that quality of life or symptoms have improved.

Time frame:
Week 1 and Week 48
Reported as:
Mean · scores on a scale
Patient Global Assessment
scores on a scaleRomiplostim in Adults
Week 1 (N=271)7.61 ± 2.02
Week 48 (N=216)8.18 ± 1.78

Adverse events

Collected over For adult participants the average duration was 110 weeks; for pediatric participants the average duration is 82 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim in Adults—117/291 (40.2%)270/291 (92.8%)
Romiplostim in Pediatric Population—2/20 (10%)18/20 (90%)
Most frequent serious events
Showing 10 of 200
Most frequent serious events
EventRomiplostim in AdultsRomiplostim in Pediatric Population
ThrombocytopeniaBlood and lymphatic system disorders23/2910/20
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders7/2911/20
InfluenzaInfections and infestations0/2911/20
Pharyngitis streptococcalInfections and infestations0/2911/20
EpistaxisRespiratory, thoracic and mediastinal disorders3/2911/20
PneumoniaInfections and infestations8/2910/20
Cardiac failure congestiveCardiac disorders5/2910/20
Myocardial infarctionCardiac disorders5/2910/20
Bone marrow disorderBlood and lymphatic system disorders4/2910/20
Cardiac failureCardiac disorders4/2910/20
Most frequent other events
Showing 10 of 72
Most frequent other events
EventRomiplostim in AdultsRomiplostim in Pediatric Population
Upper respiratory tract infectionInfections and infestations76/29110/20
PyrexiaGeneral disorders36/2919/20
HeadacheNervous system disorders109/2919/20
CoughRespiratory, thoracic and mediastinal disorders70/2919/20
PetechiaeSkin and subcutaneous tissue disorders53/2919/20
ContusionInjury, poisoning and procedural complications88/2918/20
VomitingGastrointestinal disorders46/2917/20
FatigueGeneral disorders93/2917/20
NasopharyngitisInfections and infestations100/2915/20
Nasal congestionRespiratory, thoracic and mediastinal disorders30/2916/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Romiplostim in AdultsRomiplostim in Pediatric PopulationTotal
Mean54.2 ± 16.910.2 ± 5.151.3 ± 19.7
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim in AdultsRomiplostim in Pediatric PopulationTotal
Female1846190
Male10815123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romiplostim in AdultsRomiplostim in Pediatric PopulationTotal
Black or African American13316
White or Caucasian24613259
Hispanic or Latino21425
Asian909
Japanese101
American Indian or Alaska Native101
Native Hawaiian or Other Pacific Islander101
Other011
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009 Mar 5;113(10):2161-71. doi: 10.1182/blood-2008-04-150078. Epub 2008 Nov 3. Erratum In: Blood. 2009 May 7;113(19):4822. PubMed 18981291 ↗
  • Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22. PubMed 23432528 ↗
  • Terrell D, George J, Bussel J, Lyons R, Pullarkat V, Redner R, Nie, Selleslag D, Nie K, Woodard P.Home administration of romiplostim by patients with chronic immune thrombocytopenia (ITP).Journal-001500;
  • Terrell D, George J, Bussel J, Lyons R, Pullarkat V, Redner R, Nie, Selleslag D, Nie K, Woodard P.Home administration of romiplostim by patients with chronic immune thrombocytopenia (ITP).Journal-001752;
  • Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009 Oct 29;114(18):3748-56. doi: 10.1182/blood-2009-05-224766. Epub 2009 Aug 11. PubMed 19671919 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 1, 2005
Start
Aug 2004
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Apr 6, 2011
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00116688
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 1, 2005
Start date
Aug 2004
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Apr 6, 2011
Last update
Dec 18, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion